Demecolcine
Based on 7 publication(s) in Google Scholar
Demecolcine is a potent mitotic inhibitor with an IC50 value of 2.4 μM for inhibition of tubulin polymerization. Colcemid (Demecolcine) can interact with tubulin dimers to induce anti-mitotic action and inhibit microtubule growth. Colcemid (Demecolcine) can be used for inflammatory disorders and cancer research.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 477-30-5
- Formula: C21H25NO5
- Molecular Weight:371.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Medicine Food Homology Compound Library
HY-L055
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Alkaloids Library
HY-L071
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Cancer Natural Product Library
HY-L107
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Tibetan Medicine Compound Library
HY-L191
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Demecolcine
More- Adv Sci (Weinh). 2026 Mar;13(14):e21709. [Abstract]
- Protein Cell. 2022 Jan;13(1):47-64. [Abstract]
- Clin Cancer Res. 2025 Apr 29. [Abstract]
- Cancer Lett. 2022 Oct 28:547:215855. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 16. [Abstract]
- Cancer Cell Int. 2025 Dec 18;25(1):436. [Abstract]
- Oncol Lett. 2023 Apr 19;25(6):237. [Abstract]
Customer Validation & Images
-
IP
-
IP
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | EC50 |
0.09 μM
Compound: Demecolcine
|
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
|
[PMID: 20966043] |
| HepG2 | EC50 |
12.6 μM
Compound: Demecolcine
|
Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis
|
[PMID: 20966043] |
| KB | ED50 |
<0.25 μg/mL
Compound: Demicolcine
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7130986] |
| MCF7 | EC50 |
0.6 μM
Compound: 6
|
Cytotoxicity against human MCF7 after 3 days by SRB assay
Cytotoxicity against human MCF7 after 3 days by SRB assay
|
[PMID: 15730238] |
| NCI-H460 | EC50 |
0.69 μM
Compound: 6
|
Cytotoxicity against human H460 after 3 days by SRB assay
Cytotoxicity against human H460 after 3 days by SRB assay
|
[PMID: 15730238] |
| SF-268 | EC50 |
6.2 μM
Compound: 6
|
Cytotoxicity against human SF-268 after 3 days by SRB assay
Cytotoxicity against human SF-268 after 3 days by SRB assay
|
[PMID: 15730238] |
Demecolcine (0.1-0.25 μg/ml, 1 h) reduces the the hypoploidy frequencies in metaphase II complements of mouse, rat and frog spermatocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice[3]
-
Dosage:0.3 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Elevated 7.8-8-fold of the hypoploid and hyperploid frequencies in metaphase II cells relative to controls.
Chemical Information
-
CAS No. 477-30-5
-
Appearance Solid
-
Molecular Weight 371.43
-
Formula C21H25NO5
-
Color White to light yellow
-
SMILES
O=C1C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=CC=C1OC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
ROS-Responsive Wedelolactone Hydrogel Promotes Intervertebral Disc Repair by Disrupting the NF-κB-LCN2 Inflammatory Feedback Loop. [Abstract]2026 Mar;13(14):e21709. PMID: 41487054 -
Protein Cell
cGAS guards against chromosome end-to-end fusions during mitosis and facilitates replicative senescence. [Abstract]2022 Jan;13(1):47-64. PMID: 34676498
Demecolcine purchased from MedChemExpress. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64. [Abstract]
ChIP analysis of TRF1, TRF2 and POT1 associating with telomeres in asynchronous (Asynchr) or mitotic U2OS cells. Cells were either asynchronous or synchronized at G1/S, released for 8 h and then treated with Colcemid (Demecolcine) for 12 h.
Demecolcine purchased from MedChemExpress. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64. [Abstract]
Co-IP assay to determine the domain of cGAS that interacts with CDK1. 293T cells transfected with GFP-tagged full-length (GFP-FL) or its domain (GFP-1, -2 or -3) were treated with Colcemid (Demecolcine: 1 μg/mL) for 16 h and subjected to immunoprecipitation with GFP-beads.
-
Clin Cancer Res
Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer. [Abstract]2025 Apr 29. PMID: 40299768 -
Cancer Lett
ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. [Abstract]2022 Oct 28:547:215855. PMID: 35998796 -
Acta Pharmacol Sin
PLN-L31A/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations. [Abstract]2026 Jan 16. PMID: 41545752 -
Cancer Cell Int
Machine learning identified extrachromosomal DNA-related 12 gene signatures to predict cancer immunotherapy response. [Abstract]2025 Dec 18;25(1):436. PMID: 41413526 -
Oncol Lett
Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report. [Abstract]2023 Apr 19;25(6):237. PMID: 37153052
Solvent & Solubility
DMSO : 25 mg/mL (67.31 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (13.46 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. T Tsuchida, et al. Colcemid-induced apoptosis of cultured human glioma: electron microscopic and confocal laser microscopic observation of cells sorted in different phases of cell cycle. Cytometry. 1998 Apr 1;31(4):295-9. [Content Brief]
[3]. Nett RS, et al. Discovery and engineering of colchicine alkaloid biosynthesis. Nature. 2020 Aug;584(7819):148-153. doi: 10.1038/s41586-020-2546-8. Epub 2020 Jul 22. Erratum in: Nature. 2020 Jul 30. [Content Brief]
[4]. Muzaffar A, et al. Antitubulin effects of derivatives of 3-demethylthiocolchicine, methylthio ethers of natural colchicinoids, and thioketones derived from thiocolchicine. Comparison with colchicinoids. J Med Chem. 1990 Feb;33(2):567-71. [Content Brief]
[5]. Risley MS, et al. An improved method for cytogenetic analysis of meiotic aneuploidy in rodent and frog spermatocytes. Mutat Res. 1990 Dec;234(6):361-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.6923 mL | 13.4615 mL | 26.9230 mL | 67.3074 mL |
| 5 mM | 0.5385 mL | 2.6923 mL | 5.3846 mL | 13.4615 mL | |
| 10 mM | 0.2692 mL | 1.3461 mL | 2.6923 mL | 6.7307 mL | |
| DMSO | 15 mM | 0.1795 mL | 0.8974 mL | 1.7949 mL | 4.4872 mL |
| 20 mM | 0.1346 mL | 0.6731 mL | 1.3461 mL | 3.3654 mL | |
| 25 mM | 0.1077 mL | 0.5385 mL | 1.0769 mL | 2.6923 mL | |
| 30 mM | 0.0897 mL | 0.4487 mL | 0.8974 mL | 2.2436 mL | |
| 40 mM | 0.0673 mL | 0.3365 mL | 0.6731 mL | 1.6827 mL | |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5385 mL | 1.3461 mL | |
| 60 mM | 0.0449 mL | 0.2244 mL | 0.4487 mL | 1.1218 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz